1. Introduction {#sec0005}
===============

Heteropolyacids (HPAs) as classes of inorganic compound are transition metal oxide clusters that contain W, Mo and V metals. These materials have an impressive application potential in optics, electronics, catalysis and medicines [@bib0005], [@bib0010], [@bib0015]. Rhule et al. published a review and described the applications of HPAs in medicines [@bib0020]. HPAs have been shown to exhibit antiviral activity against several RNA viruses including the orthomyxoviruses, paramyxoviruses, flaviviruses, coronaviruses, retroviruses, different influenza strains, Dengue fever virus and SARS coronavirus [@bib0025], [@bib0030], [@bib0035]. Also, HPAs have been investigated as promising anti-HIV [@bib0040] and anti-cancer agents [@bib0045], [@bib0050]. The activity of HPAs is dependent on their particle size. A novel method for synthesis of HPAs with nanometer size was introduced in this work for the first time.

Magnetothermally-triggered drug delivery systems offer a novel mechanism by which release of a drug can be triggered externally to the body [@bib0055]. When magnetic materials are exposed to a magnetic field of strength *H*, the magnetic induction (*B*) in these materials is represented by Eq. [(1)](#eq0005){ref-type="disp-formula"}:$$B = \mu_{0}(H + M)$$

Here, *μ* ~0~ is the permeability in vacuum and *M* is the magnetic moment per volume. When these materials are placed in an AC magnetic field, power dissipation of these particles from heat caused by the delay in the relaxation of the magnetic moment through either the rotation within the particle (Néel relaxation (*τ* ~N~)) or the rotation of the particle itself (Brownian relaxation (*τ* ~B~)) [@bib0060]. The effective relaxation time *τ* is given by Eq. [(2)](#eq0010){ref-type="disp-formula"}:$$\frac{1}{\tau} = \frac{1}{\tau_{\text{B}}} + \frac{1}{\tau_{\text{N}}}$$

The power dissipation is expressed as [@bib0065]:$$P = \pi\mu_{0}\chi_{0}H^{2}f\frac{2\pi f\tau}{1 + {(2\pi f\tau)}^{2}}$$where, *χ* ~0~ is the actual volumetric magnetic susceptibility, *f* is the frequency of the applied AC magnetic field. Temperature rise for these magnetic materials is related to power dissipation and computed by Eq. [(4)](#eq0020){ref-type="disp-formula"}:$$\Delta T = P\frac{\Delta t}{C}$$

Here, *C* is the fluid specific heat and Δ*t* is the duration of the heating. As shown in Eqs. [(3)](#eq0015){ref-type="disp-formula"}, [(4)](#eq0020){ref-type="disp-formula"} the temperature rise is dependent on the strength of the AC magnetic field. In most cases, higher field intensities generate more heat [@bib0070]. But in the definite temperature, the magnetic material will stop heating and reach steady state, even if the AC magnetic field is applied for a long period of time. This temperature, known as Curie temperature, which is dependent on the crystal size as nanomagnetic materials has low Curie temperature [@bib0055], [@bib0070].

Thermo-sensitive polymers have been extensively studied for controlled release drug delivery. These polymers are including poly(*N*-isopropylacrylamide) (PNIPAM) [@bib0075], [@bib0080], [@bib0085], poly(vinyl methyl ether) (PVME) [@bib0090], and poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEOePPOePEO) tri-block copolymers [@bib0095]. These polymers have a distinctive lower critical solution temperature (LCST) and are water insoluble at temperatures above their LCSTs. In water, PNIPAM hydrogels show a negative volume response to temperature, due to a phase transition occurs in the polymer configuration: they maintain a swollen (hydrophilic) state at low temperature, while they shrink remarkably to a collapsed (hydrophobic) state when the temperature is raised above 32 °C, which is PNIPAM\'s lower critical solution temperature [@bib0100]. Due to the dramatic volume phase transition properties, PNIPAM-based hydrogel has been used in the thermo-responsive controlled release [@bib0105], [@bib0110], [@bib0115], [@bib0120], [@bib0125], [@bib0130], protein adsorption and heavy metal ion adsorbent, cell detachment and so on [@bib0135], [@bib0140], [@bib0145], [@bib0150].

Recently, a number of functionalized Fe~3~O~4~ nanoparticles have been employed and the studies on immobiliztation of catalysts on silica coated ironoxide nanoparticles have been reported [@bib0155], [@bib0160], [@bib0165]. Also, in recent years, Fe~3~O~4~\@C\@PANI magnetic microspheres for the extraction and analysis of phenolic compounds and core--shell microspheres with PNIPAM core and biocompatible porous ethyl cellulose shell embedded with PNIPAM gates have been successfully prepared [@bib0170], [@bib0175].

In this work, we prepared H~3~PMo~12~O~40~ nano-drug as HPAs agents and Fe~3~O~4~\@SiO~2~/poly(*N*-isopropylacrylamide) as magnetothermally responsive carrier for the first time. Then the released behavior of H~3~PMo~12~O~40~ nano-drug from this thermo-responsive carrier in an AC magnetic field was investigated.

Furthermore, experimental condition such as strength of magnetic field (*H*), temperature (*T*), particle size and content of loaded drug which lead to the released profile of H~3~PMo~12~O~40~ nano-drug from Fe~3~O~4~\@SiO~2~/poly(*N*-isopropylacrylamide), were tested.

2. Experimental {#sec0010}
===============

2.1. Materials and physical measurements {#sec0015}
----------------------------------------

All the chemical reagents used in our experiments were of analytical grade and were used as received without further purification. X-ray powder diffraction (XRD) patterns were recorded by a Rigaku D-max C III, X-ray diffractometer using Nifiltered Cu Kα radiation. Dynamic light scatterings (DLS) were recorded on a HORIBA-LB550. Scanning electron microscopy (SEM) image was obtained on Philips XL-30ESEM. Transmission electron microscopy (TEM) images were obtained on a Philips EM208 transmission electron microscope with an accelerating voltage of 100 kV. Fourier transform infrared (FT-IR) spectra were recorded on Shimadzu Varian 4300 spectrophotometer in KBr pellets. Magnetic properties were obtained on a BHV-55 vibrating sample magnetometer (VSM).

2.2. Synthesis of H~3~PMo~12~O~40~ nano drug {#sec0020}
--------------------------------------------

H~3~PMo~12~O~40~ nanoparticles (which were labeled as PMA^n^) were prepared using the solvothermal method in an n-Octane as salvent. In a typical procedure, 5 mmol of bulk H~3~PMo~12~O~40~ (PMA^b^) was dispersed in 50 ml n-Octane and the resulting dispersion was stirred vigorously for 30 min at room temperature to form a homogeneous dispersion. This solution was transferred into a Teflon-lined stainless autoclave filling 80% of the total volume. The autoclave was sealed and maintained at 150 °C for 12 h. The autoclave was then cooled to room temperature. Finally, the resulted powder was filtered and washed for several times by n-Octane, and dried in a vacuum at 80 °C for 12 h.

2.3. Synthesis of Fe~3~O~4~@ silica mesoporous {#sec0025}
----------------------------------------------

For synthesis of Fe~3~O~4~@ silica mesoporous, Fe~3~O~4~ nanoparticles were prepared first. In a typical procedure the mixture of FeCl~3~·6H~2~O (1.3 g, 4.8 mmol) in water (15 ml) was added to the solution of CTAB (1 g), as a surfactant, and FeCl~2~·4H~2~O (0.9 g, 4.5 mmol) in water (15 ml), which was prepared by completely dissolving CTAB in water followed by addition of FeCl~2~·4H~2~O. The resultant solution was left to be stirred for 30 min in 80 °C. Then ethylenediamine (1.0 mol/l) was added drop by drop with vigorous stirring to produce a black solid product when the reaction media reaches pH 10. The resultant mixture was heated on water bath for 2 h at 60 °C and the black magnetite solid product was filtered and washed with ethanol three times and was then dried at 80 °C for 10 h.

The core--shell Fe~3~O~4~\@SiO~2~/CTAB nanospheres were prepared by a modified Stober method [@bib0180]. Briefly, Fe~3~O~4~ (0.50 g, 2.1 mmol) was dispersed in the mixture of ethanol (50 ml), deionized water (5 ml), CTAB (0.5 g) and tetraethoxysilane (TEOS) (0.20 ml), after that 5.0 ml of NaOH (10 wt%) was added. This solution was stirred mechanically for 30 min at room temperature. Then the product, Fe~3~O~4~\@SiO~2~/CTAB, was separated by an external magnet, and was washed with deionized water and ethanol three times and dried at 80 °C. For preparing Fe~3~O~4~@ silica mesoporous, the as-synthesis Fe~3~O~4~\@SiO~2~/CTAB was calcined at 600 °C.

2.4. Synthesis of Fe~3~O~4~\@silica/PIPA {#sec0030}
----------------------------------------

For synthesis of Fe~3~O~4~\@silica/PIPA, first of all *N*-isopropylacrylamide (72 mmol), *N*,*N*′-methylene-bis(acrylamide) (2 mmol) and benzoeil peroxide (2 mmol) were mixed with 50 ml acetone and were placed under a stream of nitrogen. Then 5 g of Fe~3~O~4~\@SiO~2~ synthesis was added to above solution and this solution was heated for 18 h at 60 °C. The resulting gel was filtered and washed three times with acetone. Then, for removal of unloaded PIPA from Fe~3~O~4~\@SiO~2~ and in order to excess *N*-isopropylacrylamide, *N*,*N*′-methylene-bis(acrylamide) or benzoeil peroxide, the resulting gel was redispersed in 50 ml acetone and extracted with external magnetic field [@bib0130].

2.5. Loaded of PMA^n^ in Fe~3~O~4~\@silica/PIPA {#sec0035}
-----------------------------------------------

For loading PMA^n^ in Fe~3~O~4~\@silica/PIPA, 1.0 g Fe~3~O~4~\@silica loaded with PIPA gel was added to an aqueous PMA^n^ solution and stirred for 24 h at room temperature. This procedure was repeated by PMA^b^. The loading capacity and the encapsulation efficiency of the silica nanoparticles were calculated according to the following formula:$$\text{Drug}\text{ \,\,}\text{loading}\text{ \,\,}\text{capacity} = \frac{(W_{\text{administered}\text{ \,\,}\text{dose}} - W_{\text{residual}\text{ \,\,}\text{dose}\text{ \,\,}\text{in}\text{ \,\,}\text{solution}})}{W_{\text{nano-carrier}}}$$ $$\text{Encapsulation}\text{ \,\,}\text{efficiency} = \frac{(W_{\text{administered}\text{ \,\,}\text{dose}} - W_{\text{residual}\text{ \,\,}\text{dose}\text{ \,\,}\text{in}\text{ \,\,}\text{solution}})}{W_{\text{administered}\text{ \,\,}\text{dose}}} \times 100\%$$where *W* ~administered~ ~dose~ is the weight of PMA^n^ or PMA^b^ as drug for loading, *W* ~residual~ ~dose~ ~in~ ~solution~ is the weight of residual PMA^n^ or PMA^b^ in solution after loading onto Fe~3~O~4~\@silica/PIPA nanoparticle, and *W* ~nano-carrier~ is the weight of Fe~3~O~4~\@silica/PIPA nanoparticles for loading, respectively.

2.6. In vitro release of PMA from Fe~3~O~4~\@silica/PIPA {#sec0040}
--------------------------------------------------------

In vitro release of PMA was performed by immersing 0.1 g PMA-encapsulated Fe~3~O~4~\@silica/PIPA in 50 ml simulated body fluid (SBF) at 37 °C. The SBF was prepared by dissolving reagent grade NaCl, NaHCO~3~, KCl, Na~2~HPO~4~·2H~2~O, MgCl~2~·6H~2~O, CaCl~2~·2H~2~O, and Na~2~SO~4~ in deionized water. The solution was buffered to pH 7.4 with Tris buffer and hydrochloric acid. This solution is exposed to an AC magnetic field with 350 kHz frequency. Then at predetermined time intervals, 5 ml of the solution was collected from the released medium and replaced with fresh SBF. The released PMA was analyzed by UV/vis spectrophotometer. By changing the intensity of the magnetic field, the temperature of released medium was controlled. [Table 1](#tbl0005){ref-type="table"} shows the conditions of loading and releasing of PMA in detail. Also, experimental procedure and experimental setup are shown in [Fig. 1](#fig0010){ref-type="fig"}a and b respectively.Table 1Experimental conditions of loading and releasing of PMA.Sample(mg)Loaded PMA (mg)*T* (°C)*t*~0~[a](#tblfn0005){ref-type="table-fn"} (min)*H* (G)Released PMA after 10 h (mg)Released PMA after 10 h (%)15030451552025.083.327040451552036.090.039070451552064.091.4411080451552075.093.859070351550057.582.169070401551060.085.779070502055065.092.889070552057067.596.49PMA^b^ (90 mg)3045205201033.3[^1]Fig. 1Experimental procedure (a) and experimental setup (b).

The heat generation of Fe~3~O~4~\@silica nano-carriers that were dispersed in simulated body fluid was investigated by a custom-designed magnetic-induction chamber. The concentration of Fe~3~O~4~\@silica nanoparticles aqueous suspension was adjusted to 10 mg/ml. The heating setup is composed of a power supply (Nova Star 5 kW RF Power Supply, Ameritherm, Inc., Scottsville, NY, USA), coil (Induction Atmospheres, Rochester, NY, USA) and chiller (JT1000; Refrigerant: R-134A, pressure: 200 psi, Koolant Koolers INC., Kalamazoo, MI, USA). The magnetic field was controlled by adjusting the voltages in the power supply. The rising temperatures were measured using digital thermometer every 30 s for 20 min. The temperature of the Fe~3~O~4~\@silica nano-carriers suspension (50 ml) under various AC magnetic fields was measured in the center of samples through the gaps in the coils by thermometer. These data were used to generate heating profiles for each sample. The dependence on the applied AC magnetic field of heat generation was investigated at frequencies of 350 kHz with magnetic fields ranging from 500 to 570 G.

3. Results and discussion {#sec0045}
=========================

The elemental analysis of PMA^n^ nanoparticles was estimated by ICPAES. The Mo/P ratio of the PMA^n^ was 12.4. Therefore these nanoparticles have Keggin unit cell structure because Keggin units have one central atom (P), 12 transition metal atoms (Mo) and an appropriate number of charge balancing protons or cations.

PMA with Keggin structure consisted of one PO~4~ tetrahedron surrounded by four Mo~3~O~13~ sets formed by three edge-sharing octahedra. There are four types of oxygen atoms in H~3~PMo~12~O~40~; O^\*^ (the central oxygen atoms in PO~4~ tetrahedron), O~c~ (the corner-sharing oxygen between different Mo~3~O~13~ sets), O~e~ (the edge-sharing oxygen-bridge within Mo~3~O~13~ sets), and O~t~ (the terminal oxygen atoms) [@bib0185].

[Fig. 2](#fig0015){ref-type="fig"}A shows the FT-IR spectra of (a) Fe~3~O~4~\@SiO~2~, (b) Fe~3~O~4~\@silica/PIPA, (c) H~3~PMo~12~O~40~ nanoparticle (PMA^n^), (d) H~3~PMo~12~O~40~ bulk (PMA^b^) and (e) synthesized Fe~3~O~4~\@SiO~2~/PIPA/PMA^n^ sample. Fe~3~O~4~\@SiO~2~ shows vibration bands in 561, 1000--1150, and 3400 cm^−1^, which can be attributed to the Fe---O, Si---O---Si, and ---OH bonds, respectively ([Fig. 2](#fig0015){ref-type="fig"}Aa). [Fig. 2](#fig0015){ref-type="fig"}Ab shows the FT-IR spectrum of Fe~3~O~4~\@silica/PIPA nanoparticles, the peaks at 562, 1000--1150, 1546 and 1655 cm^−1^ are attributed to Fe---O (stretching vibration), Si---O---Si (asymmetric stretching), N---H (bending) and C000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000O (stretching), respectively. The presence of several bands with medium intensity in 2850--2980 cm^−1^ region is allocated to C---H stretching of groups (symmetric and asymmetric stretching). These results indicated that poly (*N*-isopropylacrylamide) was coated on the Fe~3~O~4~\@SiO~2~ successfully. The FT-IR spectrum for PMA^n^ shows four bands corresponding to the Keggin structure at 755, 839, 955 and 1063 cm^−1^, which can be assigned to *ν* ~as~(Mo--O~e~--Mo), *ν* ~as~(Mo--O~c~--Mo), *ν* ~as~(Mo--O~t~) and *ν* ~as~(P--O^\*^), respectively ([Fig. 2](#fig0015){ref-type="fig"}Ac). It also shows a weak band in the region of 590 cm^−1^ which corresponds to the *δ*(P--O) vibration. According to FT-IR spectroscopy, the characteristic bands for PMA^n^ compared to PMA^b^, are shifted to higher wave numbers (blue shift). The binding of PMA^n^ on surfaces of Fe~3~O~4~\@silica/PIPA magnetic nanoparticles was confirmed by FTIR spectroscopy ([Fig. 2](#fig0015){ref-type="fig"}Ae). The absorption bands at 563, 1000--1150, 1544, 1653 and 2850--3000 cm^−1^ are in correspondence with vibrations of Fe---O, Si---O---Si, N---H, CO and C---H stretching in Fe~3~O~4~\@silica/PIPA nanoparticles [@bib0190], [@bib0195], [@bib0200], [@bib0205] and also, the appearance of the peaks at 756, 840, 955 and 1065 cm^−1^ that are in correspondence with PMA^n^, confirmed that PMA^n^ was coated on the Fe~3~O~4~\@silica/PIPA magnetic nanoparticles successfully. The characteristic bands for these samples are listed in [Table 2](#tbl0010){ref-type="table"} .Fig. 2(A) The FT-IR spectra of (a) Fe~3~O~4~\@SiO~2~, (b) Fe~3~O~4~\@silica/PIPA, (c) H~3~PMo~12~O~40~ nanoparticle (PMA^n^), (d) H~3~PMo~12~O~40~ bulk (PMA^b^) and (e) synthesized Fe~3~O~4~ @ SiO~2~/PIPA/PMA^n^ sample, (B) magnetization curves at 300 K for Fe~3~O~4~ (a) and Fe~3~O~4~\@silica/PIPA/PMA^n^ (b) and (C) UV spectra of PMA^b^ (a), PMA^n^ (b) and Fe~3~O~4~\@silica/PIPA/PMA^n^ (c). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)Table 2The characteristic bands of PMA^n^ and Fe~3~O~4~\@silica/PIPA/PMA^n^.SamplePMA^n^Fe~3~O~4~\@silica/PIPA/PMA^n^O^\*^O~c~O~e~O~t~Fe---OSi---O---SiC---HCON---HWavenumber (cm^−1^)10638397559555631000--11502850--300016531544

The magnetic properties of the samples were studied by a vibrating sample magnetometer at 300 K. [Fig. 2](#fig0015){ref-type="fig"}Ba and b show the magnetic hysteresis loops of Fe~3~O~4~ and Fe~3~O~4~\@silica/PIPA/PMA^n^ respectively. As it is shown, the hysteresis phenomenon was not found and the magnetization and demagnetization curves were coincident. This indicated that all products had super-para magnetism at room temperature. The saturation magnetization values for Fe~3~O~4~ and Fe~3~O~4~\@silica/PIPA/PMA^n^ were 65.0 and 46.0 emu/g, respectively

X-ray powder diffraction patterns of PMA^n^ and Fe~3~O~4~\@silica/PIPA/PMA^n^ are shown in [Fig. 3](#fig0020){ref-type="fig"}a and b respectively. The strong characteristic peaks at 2*θ*  = 9.05°, 23.7°, 26.35°, 28.25° and 32.4° in [Fig. 3](#fig0020){ref-type="fig"}a, are assigned to Keggin structure of PMA \[JCPDS File 1-32\] [@bib0210]. No other peak exists in this pattern, showing the high purity and well crystallinity of the samples. The characteristic peaks in [Fig. 3](#fig0020){ref-type="fig"}b, which were indicated by star (\*) corresponded with cubic Fe~3~O~4~ (JCPDS\# 19-629) [@bib0215]. From XRD data, the crystallite size (*D* ~c~) of the as-prepared PMA^n^, were calculated using the Debey--Scherrer equation [@bib0220],$$D_{\text{c}} = \frac{K\lambda}{\beta\cos\,\theta}$$where, *β* is the breadth of the observed diffraction line at its half-intensity maximum, *k* is the so-called shape factor, which usually takes a value of about 0.9, and *k* is the wavelength of X-ray source used in XRD. The average size of the PMA^n^, were calculated to be 18 nm, which is to some extent in agreement with the one observed from TEM and DLS images.Fig. 3XRD patterns of PMA^n^ (a) and Fe~3~O~4~\@silica/PIPA/PMA^n^ (b).

TEM and DLS images of the nanoparticels have been represented in [Fig. 4](#fig0025){ref-type="fig"}, [Fig. 5](#fig0030){ref-type="fig"} . [Fig. 4](#fig0025){ref-type="fig"}a--d shows TEM images of Fe~3~O~4~, PMA^n^, Fe~3~O~4~\@silica and Fe~3~O~4~\@silica/PIPA/PMA^n^ respectively. The size of nanoparticles obtained from the TEM images, which shows 17, 15 and 50 nm for PMA^n^, Fe~3~O~4~ and Fe~3~O~4~\@silica/PIPA/PMA^n^ respectively, and their shapes are nearly spherical.Fig. 4TEM images of Fe~3~O~4~ (a), PMA^n^ (b), Fe~3~O~4~\@silica (c) and Fe~3~O~4~\@silica/PIPA/PMA^n^ (d) respectively and SEM image of Fe~3~O~4~\@silica/PIPA/PMA^n^ (e).Fig. 5Particle size histograms of Fe~3~O~4~ (a), PMA^n^ (b), Fe~3~O~4~\@silica (c) and Fe~3~O~4~\@silica/PIPA/PMA^n^ (d) respectively.

To investigate the size distribution of these nanoparticles, particle size histograms were prepared for Fe~3~O~4~, PMA^n^, Fe~3~O~4~\@silica and Fe~3~O~4~\@silica/PIPA/PMA^n^ ([Fig. 5](#fig0030){ref-type="fig"}a--d respectively) by DLS analysis. This size distribution is centered at a value of 12, 15, 35 and 45 nm for Fe~3~O~4~, PMA^n^, Fe~3~O~4~\@silica and Fe~3~O~4~\@silica/PIPA/PMA^n^ respectively. [Fig. 4](#fig0025){ref-type="fig"}e show SEM images of Fe~3~O~4~\@silica/PIPA/PMA^n^. As it is shown, these nanoparticles have spherical shapes with approximately 55 nm diameters.

In vitro release of PMA^n^ from the nano porous Fe~3~O~4~\@silica/PIPA/PMA^n^ carrier was investigated. The drug loading and drug release content were measured from UV absorbance spectra on the basis of Beer--Lambert law:$$A = \varepsilon cb$$where, *A* is the absorption intensity, *c* is the PMA^n^ concentration, *b* is the path length of the radiation through the absorbing medium and *ɛ* is a proportionality constant. UV absorbance spectra of PMA^n^ and Fe~3~O~4~\@silica/PIPA/PMA^n^ are shown in [Fig. 2](#fig0015){ref-type="fig"}Ca and b respectively. By using UV data, PMA^n^ exhibit absorptions at *λ* ~max~  = 350 nm [@bib0210].

The release profiles of PMA^n^ from Fe~3~O~4~\@silica/PIPA/PMA^n^ for sample 1--4 are shown in [Fig. 6](#fig0035){ref-type="fig"}a and b. As it is shown, with increases in loading content of drug in Fe~3~O~4~\@silica/PIPA/PMA^n^ the release rate and the extent of released drug are increased. This may be due to the fact that the PMA is more soluble in the water than in PIPA and with the increase of the ratio of PIPA to PMA, the content of the free water in the hydrogels decreased.Fig. 6The release profiles of PMA from Fe~3~O~4~\@silica/PIPA/PMA in different loaded PMA (a and b). The release profiles of PMA from Fe~3~O~4~\@silica/PIPA/PMA in different (c) temperature and (d) strength of magnetic field.

According to Noyes--Whitney equation the dissolution rate is related to surface area:$$\frac{dC}{dt} = kA(C_{\text{s}} - C)$$where *dC*/*dt*, *k*, *A*, *C* ~s~ and *C* are dissolution rate, dissolution rate constant, saturation solubility of the drug and concentration of drug in the bulk solution respectively. By decreasing the size of drug to nanometer range the total surface area is increased; therefore the rate of dissolution and the rate of release are increased. As it is shown in [Fig. 6](#fig0035){ref-type="fig"}b PMA^b^ has the slower release rate than PMA^n^.

The release behavior of PMA^n^ from Fe~3~O~4~\@silica/PIPA/PMA^n^ in different temperature or strength of magnetic field was investigated and the results are presented in [Fig. 6](#fig0035){ref-type="fig"}c and d. It is well known that the solubility of PIPA in aqueous solution reduces with increasing temperature [@bib0030]. PIPA has been reported to have a lower critical solution temperature which is near 32 °C in water, based on viscosity, light scattering, and DSC studies [@bib0025]. As it is shown, PMA^n^ was released much faster by increasing the temperature from 35 to 55 °C ([Fig. 6](#fig0035){ref-type="fig"}a), or increasing the strength of magnetic field from 500 to 570 G ([Fig. 6](#fig0035){ref-type="fig"}b). This can be explained by the fact that the solubility is decreased due to a weakening of the ordering effect of the water--amide hydrogen bonds between the polymers as the temperature increases [@bib0100]. The data from [Fig. 6](#fig0035){ref-type="fig"}c and d suggest that the PIPA gel in the Fe~3~O~4~\@silica pores swells below the LCST (32 °C), and thus the PMA^n^ in the silica--PIPA gel cannot easily permeate through the pore. Above the LCST (32 °C) the PIPA gel shrinks so that PMA^n^ can easily be released through the pore.

4. Conclusions {#sec0050}
==============

For a drug to be absorbed, it must first be dissolved. By reducing the particle size to nanometer range, the total surface area, the rate of dissolution and the therapeutic response of a drug would increase. In this work, a new method is introduced for synthesis of nano drug; the particle size of H~3~PMo~12~O~40~ is reduced to 15 nm by solvothermal method for the first time.

Fe~3~O~4~\@SiO~2~/poly(*N*-isopropylacrylamide) is synthesized as a novel magnetothermally responsive carrier for H~3~PMo~12~O~40~ nano drug and characterized by TEM, SEM, DLS, FT-IR and XRD. Then the released behavior of H~3~PMo~12~O~40~ nano-drug from this thermo-responsive carrier in an AC magnetic field was investigated. The rate of drug release is governed by:1.The particle size of drug.2.The strength of magnetic field.3.The temperature of release medium.4.The content of loaded drug.

By increasing the temperature from 35 to 55 °C, PMA^n^ was released much faster because above the LCST (32 °C) the PIPA gel shrinks so that PMA^n^ can easily be released through the pore. By increases in loading content of drug in the carrier the release rate and the extent of released drug are increased.
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[^1]: Time required for constant temperature.
